139 related articles for article (PubMed ID: 34717914)
1. The hepatocyte export carrier inhibition assay improves the separation of hepatotoxic from non-hepatotoxic compounds.
Brecklinghaus T; Albrecht W; Kappenberg F; Duda J; Vartak N; Edlund K; Marchan R; Ghallab A; Cadenas C; Günther G; Leist M; Zhang M; Gardner I; Reinders J; Russel FG; Foster AJ; Williams DP; Damle-Vartak A; Grandits M; Ecker G; Kittana N; Rahnenführer J; Hengstler JG
Chem Biol Interact; 2022 Jan; 351():109728. PubMed ID: 34717914
[TBL] [Abstract][Full Text] [Related]
2. A Two-Tiered In Vitro Approach to De-Risk Drug Candidates for Potential Bile Salt Export Pump Inhibition Liabilities in Drug Discovery.
Hafey MJ; Houle R; Tanis KQ; Knemeyer I; Shang J; Chen Q; Baudy A; Monroe J; Sistare FD; Evers R
Drug Metab Dispos; 2020 Nov; 48(11):1147-1160. PubMed ID: 32943412
[TBL] [Abstract][Full Text] [Related]
3. Prediction of human drug-induced liver injury (DILI) in relation to oral doses and blood concentrations.
Albrecht W; Kappenberg F; Brecklinghaus T; Stoeber R; Marchan R; Zhang M; Ebbert K; Kirschner H; Grinberg M; Leist M; Moritz W; Cadenas C; Ghallab A; Reinders J; Vartak N; van Thriel C; Golka K; Tolosa L; Castell JV; Damm G; Seehofer D; Lampen A; Braeuning A; Buhrke T; Behr AC; Oberemm A; Gu X; Kittana N; van de Water B; Kreiling R; Fayyaz S; van Aerts L; Smedsrød B; Ellinger-Ziegelbauer H; Steger-Hartmann T; Gundert-Remy U; Zeigerer A; Ullrich A; Runge D; Lee SML; Schiergens TS; Kuepfer L; Aguayo-Orozco A; Sachinidis A; Edlund K; Gardner I; Rahnenführer J; Hengstler JG
Arch Toxicol; 2019 Jun; 93(6):1609-1637. PubMed ID: 31250071
[TBL] [Abstract][Full Text] [Related]
4. In vitro/in silico prediction of drug induced steatosis in relation to oral doses and blood concentrations by the Nile Red assay.
Brecklinghaus T; Albrecht W; Duda J; Kappenberg F; Gründler L; Edlund K; Marchan R; Ghallab A; Cadenas C; Rieck A; Vartak N; Tolosa L; Castell JV; Gardner I; Halilbasic E; Trauner M; Ullrich A; Zeigerer A; Demirci Turgunbayer Ö; Damm G; Seehofer D; Rahnenführer J; Hengstler JG
Toxicol Lett; 2022 Sep; 368():33-46. PubMed ID: 35963427
[TBL] [Abstract][Full Text] [Related]
5. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Morgan RE; van Staden CJ; Chen Y; Kalyanaraman N; Kalanzi J; Dunn RT; Afshari CA; Hamadeh HK
Toxicol Sci; 2013 Nov; 136(1):216-41. PubMed ID: 23956101
[TBL] [Abstract][Full Text] [Related]
6. Influence of bile acids on the cytotoxicity of chemicals in cultivated human hepatocytes.
Brecklinghaus T; Albrecht W; Kappenberg F; Duda J; Zhang M; Gardner I; Marchan R; Ghallab A; Demirci Turgunbayer Ö; Rahnenführer J; Hengstler JG
Toxicol In Vitro; 2022 Jun; 81():105344. PubMed ID: 35263627
[TBL] [Abstract][Full Text] [Related]
7. The C-DILI™ Assay: An Integrated In Vitro Approach to Predict Cholestatic Hepatotoxicity.
Jackson JP; Brouwer KR
Methods Mol Biol; 2019; 1981():75-85. PubMed ID: 31016648
[TBL] [Abstract][Full Text] [Related]
8. Quantitative systems toxicology (QST) reproduces species differences in PF-04895162 liver safety due to combined mitochondrial and bile acid toxicity.
Generaux G; Lakhani VV; Yang Y; Nadanaciva S; Qiu L; Riccardi K; Di L; Howell BA; Siler SQ; Watkins PB; Barton HA; Aleo MD; Shoda LKM
Pharmacol Res Perspect; 2019 Dec; 7(6):e00523. PubMed ID: 31624633
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Drug-Induced Liver Injury Prediction: Criteria Optimization of Efflux Transporter IC50 and Physicochemical Properties.
Yucha RW; He K; Shi Q; Cai L; Nakashita Y; Xia CQ; Liao M
Toxicol Sci; 2017 Jun; 157(2):487-499. PubMed ID: 28369588
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of bile salt transport by drugs associated with liver injury in primary hepatocytes from human, monkey, dog, rat, and mouse.
Zhang J; He K; Cai L; Chen YC; Yang Y; Shi Q; Woolf TF; Ge W; Guo L; Borlak J; Tong W
Chem Biol Interact; 2016 Aug; 255():45-54. PubMed ID: 27000539
[TBL] [Abstract][Full Text] [Related]
11. In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk.
Norona LM; Fullerton A; Lawson C; Leung L; Brumm J; Kiyota T; Maher J; Khojasteh C; Proctor WR
Arch Toxicol; 2020 Sep; 94(9):3185-3200. PubMed ID: 32583097
[TBL] [Abstract][Full Text] [Related]
12. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.
Feng B; Xu JJ; Bi YA; Mireles R; Davidson R; Duignan DB; Campbell S; Kostrubsky VE; Dunn MC; Smith AR; Wang HF
Toxicol Sci; 2009 Apr; 108(2):492-500. PubMed ID: 19223659
[TBL] [Abstract][Full Text] [Related]
13. Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).
Pedersen JM; Matsson P; Bergström CA; Hoogstraate J; Norén A; LeCluyse EL; Artursson P
Toxicol Sci; 2013 Dec; 136(2):328-43. PubMed ID: 24014644
[TBL] [Abstract][Full Text] [Related]
14. Effect of a Common Genetic Variant (p.V444A) in the Bile Salt Export Pump on the Inhibition of Bile Acid Transport by Cholestatic Medications.
Ali I; Khalid S; Stieger B; Brouwer KLR
Mol Pharm; 2019 Mar; 16(3):1406-1411. PubMed ID: 30608704
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte-based in vitro model for assessment of drug-induced cholestasis.
Chatterjee S; Richert L; Augustijns P; Annaert P
Toxicol Appl Pharmacol; 2014 Jan; 274(1):124-36. PubMed ID: 24211272
[TBL] [Abstract][Full Text] [Related]
16. In vitro model systems to investigate bile salt export pump (BSEP) activity and drug interactions: A review.
Cheng Y; Woolf TF; Gan J; He K
Chem Biol Interact; 2016 Aug; 255():23-30. PubMed ID: 26683212
[TBL] [Abstract][Full Text] [Related]
17. High-Throughput Screening to Evaluate Inhibition of Bile Acid Transporters Using Human Hepatocytes Isolated From Chimeric Mice.
Kohara H; Bajaj P; Yamanaka K; Miyawaki A; Harada K; Miyamoto K; Matsui T; Okai Y; Wagoner M; Shinozawa T
Toxicol Sci; 2020 Feb; 173(2):347-361. PubMed ID: 31722436
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4.
Köck K; Ferslew BC; Netterberg I; Yang K; Urban TJ; Swaan PW; Stewart PW; Brouwer KL
Drug Metab Dispos; 2014 Apr; 42(4):665-74. PubMed ID: 24154606
[TBL] [Abstract][Full Text] [Related]
19. Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes.
Ogimura E; Sekine S; Horie T
Biochem Biophys Res Commun; 2011 Dec; 416(3-4):313-7. PubMed ID: 22108051
[TBL] [Abstract][Full Text] [Related]
20. Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective.
Kenna JG; Taskar KS; Battista C; Bourdet DL; Brouwer KLR; Brouwer KR; Dai D; Funk C; Hafey MJ; Lai Y; Maher J; Pak YA; Pedersen JM; Polli JW; Rodrigues AD; Watkins PB; Yang K; Yucha RW;
Clin Pharmacol Ther; 2018 Nov; 104(5):916-932. PubMed ID: 30137645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
